Search - tctmd.com

Displaying 61 - 80 of 154

Sort: Relevancy | Date

News Conference News AHA 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

Shelley Wood

November 13, 2020

News Daily News

H. Pylori in ACS: Could Tests and Treatment Beat Back the Bleeds?

Shelley Wood

November 05, 2020

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Daily News

Hostility After ACS Linked to All-Cause Mortality

Michael O'Riordan

September 21, 2020

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

Presentation AHA 2019

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Presenter: Matthew Budoff

November 18, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

Advertisement

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

H. Pylori in ACS: Could Tests and Treatment Beat Back the Bleeds?

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Hostility After ACS Linked to All-Cause Mortality

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Outcome Differences Between Men and Women With PAD: EUCLID Insights

FDA Approves Icosapent Ethyl for Reducing CVD Events

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content